Peregrine Pharmaceuticals reported $35.3M in Operating Expenses for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Agenus AGEN:US USD 88.08M 23.66M
Amgen AMGN:US USD 4.61B 695M
AstraZeneca AZN:LN USD 10.11B 376M
Biocryst Pharmaceuticals BCRX:US USD 125.86M 32.58M
Bristol Myers Squibb BMY:US USD 9.46B 716M
Celldex Therapeutics CLDX:US USD 29.5M 1.4M
Eli Lilly And LLY:US USD 5.47B 200.3M
GlaxoSmithKline GSK:LN GBP 5.51B 1.13B
Immunogen IMGN:US USD 100.73M 7.92M
Intrexon XON:US USD 23.56M 776K
Karyopharm Therapeutics KPTI:US USD 67.45M 465K
Macrogenics MGNX:US USD 61.12M 5.57M
Mannkind MNKD:US USD 48.85M 6.41M
Merk MRK:US USD 10.32B 624M
Minerva Neurosciences NERV:US USD 5.07M 137.42K
Newlink Genetics NLNK:US USD 9.35M 1.3M
Novartis NOVN:VX USD 11.05B 378M
Novavax NVAX:US USD 601.28M 260.49M
Peregrine Pharmaceuticals PPHM:US USD 35.3M 2.14M
Repligen RGEN:US USD 137.92M 10.15M
Roche Holding ROG:VX 25.06B 4.31B
Xencor XNCR:US USD 64.3M 1.34M